Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q1 2024 · 10-Q
Revenue$62.42M$62.42M+44.7% vs Q1 2023 Net Income-$20.24M-$20.24MN/M vs Q1 2023 EPS Diluted-$0.78-$0.78N/M vs Q1 2023 Gross Profit$37,411,000+145.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flow-$16,413,000N/M Free Cash Flowderived-$16,856,000N/M Margins · derivedGross margin59.9%+24.6 pt vs Q1 2023
Operating margin-21.9%+118.0 pt vs Q1 2023
Net margin-32.4%+109.0 pt vs Q1 2023
ended Mar 31, 2024 · filed Apr 29, 2024 · 29 d after period end